title: Application of systems pharmacology to explore mechanisms of hepatotoxicity.
abstract: Advances in systems biology have allowed the development of a highly characterized systems pharmacology model to study mechanisms of drug-induced hepatotoxicity. In this issue of CPT, Yang et al. describe a model, DILIsym, used to characterize mechanisms of hepatotoxicity of troglitazone. Their modeling approach has provided new insight into troglitazone-induced hepatotoxicity in humans but is not associated with hepatotoxicity in rats, consistent with preclinical data for this drug.
authors.affiliation: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: J
authors.initials: J
authors.lastname: Shon
authors.affiliation: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Abernethy
mesh_terms: D000818:Animals; D001647:Bile Acids and Salts / Q000502:physiology*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002839:Chromans / Q000633:toxicity*; D006801:Humans; D007004:Hypoglycemic Agents / Q000633:toxicity*; D008297:Male; D045162:Thiazolidinediones / Q000633:toxicity*; D000077288:Troglitazone
chemical_list: D001647:Bile Acids and Salts; D002839:Chromans; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077288:Troglitazone